Contact person
Mads Nybo, E- mail: mads.nybo@rsyd.dk
Associate Professor, MD, PhD, Chief Physician, Department of Clinical Biochemistry, https://portal.findresearcher.sdu.dk/en/persons/mnybo
Research aim
Our aim is to disclose relevant aspects in the preanalytical, analytical and postanalytical phase related to standard/routine biomarkers performed at established platforms. Also, to support and use data extraction for reference intervals, demand management projects and studies of a more epidemiological nature.
Project examples
- Sixteen years of creatinine measurements among 460 000 individuals-The Funen Laboratory Cohort (FLaC), a population-based pharmaco-epidemiological resource to study drug-induced kidney disease
- Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome (PCOS)
- Hemolysis as a potential biomarker of occult disease
Available cohorts and infrastructures
The Funen Laboratory Cohort (FLaC)
Collaborators
- Daniel P. Henriksen, Department of Clinical Pharmacology, OUH
- Janne Cadamuro, Uniklinikum Salzburg, Austria
- The Nordic Preanalytical Scientific Working Group (under NFKK)
Publication examples
- Hansen RS, Revsholm J, Henriksen DP, Lund LC, Nybo M. Diagnoses and mortality in a population without acute myocardial infarction, but with elevated high-sensitive troponin I - a retrospective register-based single center study. Acute Med 2021;20:18-24
- Gils C, Sandberg MB, Nybo M. Verification of the hemolysis index measurement: imprecision, accuracy, measuring range, reference interval and impact of implementing analytically and clinically derived sample rejection criteria. Scand J Clin Lab Invest 2020;80:580-9
- Kristensen MS, Green A, Nybo M, Hede SM, Mikkelsen KH, Gislason G, Larsen ML, Ersbøll AK. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study. BMC Cardiovasc Disord 2020;20:336.